http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009144846-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009144846-A |
| titleOfInvention | USING THE S1P RECEPTOR MODULATOR |
| abstract | 1. A method of preventing, suppressing or treating depression caused by the production of brain neurotrophic factor (UFHM) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an S1P receptor modulator selected from the group consisting of 2-amino-2 - [4- (3-benzyloxyphenylthio) -2-chlorophenyl] -2-ethyl-propane-1,3-diol, 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) ethyl] - 2-ethyl-benzyl} -azetidine-3-carboxylic acid and 2-amino-2- [2- (4-octylphenyl) ethyl] propan-1,3-diol or in each case tea of their pharmaceutically acceptable salts and / or their phosphorylated forms. ! 2. The method according to claim 1, wherein the S1P receptor modulator is 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol or a pharmaceutically acceptable salt thereof. ! 3. The method according to claim 1, wherein the S1P receptor modulator is 1-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol hydrochloride. ! 4. The method according to claim 1, wherein the S1P receptor modulator is 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] -2-ethyl-propan-1,3-diol or a pharmaceutically acceptable thereof salt. ! 5. The method according to claim 1, wherein the S1P receptor modulator is 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) ethyl] -2-ethyl-benzyl} -azetidine-3-carboxyl an acid or a pharmaceutically acceptable salt thereof. ! 6. The method according to any one of claims 1 to 5, in which the S1P receptor modulator is administered periodically. ! 7. The method according to any one of claims 1 to 5, which includes co-administering, for example concomitant or sequential, a therapeutically effective non-toxic amount of an S1P receptor modulator in accordance with any one of claims 1 to 5 and a second therapeutic substance. ! 8. Note |
| priorityDate | 2007-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.